Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) will likely be releasing its earnings data before the market opens on Monday, April 7th. Analysts expect Phio Pharmaceuticals to post earnings of ($1.23) per share for the quarter.
Phio Pharmaceuticals Stock Down 8.5 %
NASDAQ PHIO opened at $1.07 on Friday. The firm has a market cap of $7.37 million, a price-to-earnings ratio of -0.10 and a beta of 1.09. The company has a 50-day simple moving average of $1.58 and a two-hundred day simple moving average of $2.35. Phio Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $9.79.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
See Also
- Five stocks we like better than Phio Pharmaceuticals
- Following Congress Stock Trades
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- 3 Stocks to Consider Buying in October
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- What Are Dividends? Buy the Best Dividend Stocks
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
